Importantly, in GLA-deficient podocytes in an in vitro model of FD, the accumulation of α-synuclein (SNCA) was found to be the key mechanism of podocyte injury, where enzyme replacement therapy reduced Gb3 accumulation without the resolution of lysosomal dysfunction [182]. The gene discussed is SNCA; the disease is Fabry disease.